Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Long-term Monitoring Gait Analysis Using a Wearable Device in Daily Lives of Patients with Parkinson's Disease: The Efficacy of Selegiline Hydrochloride for Gait Disturbance.

Iijima M, Mitoma H, Uchiyama S, Kitagawa K.

Front Neurol. 2017 Oct 24;8:542. doi: 10.3389/fneur.2017.00542. eCollection 2017.

2.

A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease.

Mizuno Y, Hattori N, Kondo T, Nomoto M, Origasa H, Takahashi R, Yamamoto M, Yanagisawa N.

Clin Neuropharmacol. 2017 Sep/Oct;40(5):201-207. doi: 10.1097/WNF.0000000000000239.

3.

Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis.

Zhuo C, Xue R, Luo L, Ji F, Tian H, Qu H, Lin X, Jiang R, Tao R.

Medicine (Baltimore). 2017 Jun;96(22):e6698. doi: 10.1097/MD.0000000000006698. Review.

4.

Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.

Cereda E, Cilia R, Canesi M, Tesei S, Mariani CB, Zecchinelli AL, Pezzoli G.

J Neurol. 2017 Jun;264(6):1254-1263. doi: 10.1007/s00415-017-8523-y. Epub 2017 May 26. Erratum in: J Neurol. 2017 Aug 22;:.

5.

Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology.

Finberg JP, Rabey JM.

Front Pharmacol. 2016 Oct 18;7:340. eCollection 2016. Review.

6.

A review of disease progression models of Parkinson's disease and applications in clinical trials.

Venuto CS, Potter NB, Dorsey ER, Kieburtz K.

Mov Disord. 2016 Jul;31(7):947-956. doi: 10.1002/mds.26644. Epub 2016 May 26. Review.

7.

Freezing of Gait in Parkinsonism and its Potential Drug Treatment.

Zhang LL, Canning SD, Wang XP.

Curr Neuropharmacol. 2016;14(4):302-6. Review.

8.
10.

2-acetylphenol analogs as potent reversible monoamine oxidase inhibitors.

Legoabe LJ, Petzer A, Petzer JP.

Drug Des Devel Ther. 2015 Jul 15;9:3635-44. doi: 10.2147/DDDT.S86225. eCollection 2015.

11.

Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study.

Dashtipour K, Chen JJ, Kani C, Bahjri K, Ghamsary M.

Pharmacotherapy. 2015 Jul;35(7):681-6. doi: 10.1002/phar.1611. Epub 2015 Jul 3.

12.

Treatment of advanced Parkinson's disease.

Giugni JC, Okun MS.

Curr Opin Neurol. 2014 Aug;27(4):450-60. doi: 10.1097/WCO.0000000000000118. Review.

13.

Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments.

Bargiotas P, Konitsiotis S.

Neuropsychiatr Dis Treat. 2013;9:1605-17. doi: 10.2147/NDT.S36693. Epub 2013 Oct 22. Review.

14.

Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease.

Teo KC, Ho SL.

Transl Neurodegener. 2013 Sep 8;2(1):19. doi: 10.1186/2047-9158-2-19.

15.

Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease.

Zhang J, Mattison HA, Liu C, Ginghina C, Auinger P, McDermott MP, Stewart T, Kang UJ; Parkinson Study Group DATATOP Investigators, Cain KC, Shi M.

Acta Neuropathol. 2013 Nov;126(5):671-82. doi: 10.1007/s00401-013-1121-x. Epub 2013 May 4.

16.

Amantadine for freezing of gait in patients with Parkinson disease.

Malkani R, Zadikoff C, Melen O, Videnovic A, Borushko E, Simuni T.

Clin Neuropharmacol. 2012 Nov-Dec;35(6):266-8. doi: 10.1097/WNF.0b013e31826e3406.

17.

Medical management of Parkinson's disease: focus on neuroprotection.

Boll MC, Alcaraz-Zubeldia M, Rios C.

Curr Neuropharmacol. 2011 Jun;9(2):350-9. doi: 10.2174/157015911795596577.

18.

MAO-inhibitors in Parkinson's Disease.

Riederer P, Laux G.

Exp Neurobiol. 2011 Mar;20(1):1-17. doi: 10.5607/en.2011.20.1.1. Epub 2011 Mar 31.

19.

Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.

Robottom BJ.

Patient Prefer Adherence. 2011 Jan 20;5:57-64. doi: 10.2147/PPA.S11182.

20.

Astrocytes and therapeutics for Parkinson's disease.

Rappold PM, Tieu K.

Neurotherapeutics. 2010 Oct;7(4):413-23. doi: 10.1016/j.nurt.2010.07.001. Review.

Supplemental Content

Support Center